CASE REPORT

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

Yukino Yatsuda, Suguru Hirose, Yoshimi Ito, Tsubasa Onoda, Yutaro Sugiyama, Miho Nagafuchi, Hirosumi Suzuki, Yusuke Niisato, Yositaka Tange, Takaumi Ikeda, Takeshi Yamada, Yoshiyuki Yamamoto, Mariko Ohyama Osawa, Noriaki Sakamoto, Toshikazu Moriwaki and Yuji Mizokami

Abstract:
A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab. A 65-year-old man was treated with nivolumab as a sixth-line therapy for recurrent gastric cancer. After four cycles of nivolumab therapy, he showed a partial response. But the treatment was discontinued when two immune-related adverse events occurred after six cycles. Disease regression was sustained for approximately 2 years, without the re-administration of nivolumab. The characteristics leading to such responses are unclear, and further studies are warranted in this regard.

Key words: gastric cancer, nivolumab, durable response, immune checkpoint inhibitor, immune-related adverse event, PD-1

Introduction
Nivolumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), has been shown to provide remarkable efficacy in the treatment of patients with various kinds of malignant tumors and it is approved for the treatment of several cancers, including melanoma (1), non-small cell lung cancer (NSCLC) (2), renal cell carcinoma (RCC) (3), squamous cell carcinoma of the head and neck (4), and Hodgkin’s lymphoma (5). The ATTRACTION-2 study was conducted to investigate the efficacy and safety of nivolumab for heavily pretreated advanced gastric cancer (AGC) patients (6). This randomized, double-blind, placebo-controlled phase 3 trial showed the superiority of nivolumab over a placebo, with an objective response rate of 11.2% [95% confidence interval (CI): 7.7-15.6], a median progression-free survival (PFS) of 1.61 months (95% CI: 1.54-2.30), and a median overall survival (OS) of 5.26 months (95% CI: 4.60-6.37). Based on the results of this study, nivolumab was approved for AGC as either a third- or later-line treatment, and it has been recently recognized as a standard chemotherapeutic regimen in Japan.

Unlike in the case of conventional cytotoxic anticancer drugs or molecular targeted drugs, the blockade of the PD-1 pathway confers an adaptive memory immune response that resets the equilibrium between the tumor and host immune responses, thus indicating its potential to sustain an antitumor response even after treatment cessation (7). Recent studies have reported cases wherein a durable response was observed even after the discontinuation of therapy with immune checkpoint inhibitors (ICIs), including nivolumab, in melanoma, NSCLC, and RCC (8-10), but no such studies have so far been reported in patients with AGC.

Thus, in this study, we report a rare case of an AGC patient who maintained a durable response for approximately 2 years after the discontinuation of nivolumab.
years after the discontinuation of nivolumab due to immune-related adverse events (irAEs).

**Case Report**

The patient was a 65-year-old man who had been diagnosed with gastric cancer and had undergone total gastrectomy with D2 dissection 7.5 years previously, namely in August 2010. The pathological diagnosis was of a moderately differentiated HER2-negative, pT1N1, pStage IB adenocarcinoma. Six months postoperatively, a solitary liver metastasis was discovered. He then received S-1 treatment as palliative chemotherapy 7 years perviously in March 2011, following which he received nab-paclitaxel alone from May 2013, irinotecan alone from February 2016, capecitabine plus oxaliplatin from June 2016, and ramucirumab alone from February 2017. The disappearance of liver metastasis was observed after the administration of nab-paclitaxel alone. However, treatment with S-1, irinotecan, and ramucirumab was considered to be a failure owing to multiple abdominal lymph node metastases, portal tumor thrombus, and solitary lung metastasis, respectively (Fig. 1A).

Since he exhibited an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, he began to receive nivolumab as sixth-line therapy from March 2018. The laboratory data showed no abnormal findings (Table). The carcinoembryonic antigen and carbohydrate antigen 19-9 levels were within the normal range, which were similar to his preoperative levels. The patient’s clinical course during nivolumab treatment is shown in Fig. 2. No adverse events were observed during the first five cycles of nivolumab therapy. However, after the sixth cycle, 15 weeks after the initial treatment, he was hospitalized for severe fatigue (grade 3 by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0). During hospitalization, he exhibited ECOG PS 3. Physical examination revealed that his body temperature was 36.8°C, blood pressure was 81/48 mmHg, pulse rate was 88/min, and oxygen saturation was 99% on room air. No other abnormal findings were identified. A serum examination revealed a decreased level of thyroid-stimulating hormone (TSH) and increased levels of free triiodothyronine and free thyroxine (T4) compared with the levels before nivolumab initiation (Table).
The patient tested negative for thyroid autoantibodies. In addition, there was a decrease in the levels of adrenocorticotropic hormone (ACTH) and cortisol. A stimulation test revealed a minor impact of corticotropin-releasing hormone loading on the ACTH and cortisol levels, while growth hormone, luteinizing hormone, follicle-stimulating hormone, prolactin, and TSH showed sufficient responses according to the corresponding stimulation tests. The ultrasound findings of the thyroid and magnetic resonance imaging findings of the pituitary gland showed no abnormalities. Consequently, he was diagnosed to have grade 3 isolated ACTH deficiency with secondary adrenal insufficiency and nivolumab-related grade 3 destructive thyroiditis. Nivolumab therapy was discontinued and prednisolone was supplemented at a starting dose of 15 mg/day for adrenal insufficiency. The patient’s fatigue was alleviated within a few days, following which the prednisolone dose was tapered. His serum cortisol level returned to normal, whereas ACTH deficiency persisted. Prednisolone was maintained at a dosage of 5 mg/day since day 37, and no relapse was noted thereafter. The free T4 level decreased on day 23, confirming the hypothyroidism phase of destructive thyroiditis. Levothyroxine (25 μg/day) was administrated until the free T4 level recovered on day 95, and no relapse occurred thereafter.

After four cycles of nivolumab (approximately 2 months after the start of nivolumab therapy), all metastatic lesions shrank to around 61.2% of the size before nivolumab treatment (Fig. 1B). We determined to observe his course without the re-administration of nivolumab even after the improvement of irAEs. The metastatic lesions further decreased in size after the discontinuation of nivolumab, and the effect was sustained for 23 months after nivolumab initiation (final size, 39.1% of that before nivolumab treatment) (Fig. 1C); the tumor markers were within the normal ranges.

**Discussion**

Recently, a durable response after the discontinuation of ICIs in patients with residual disease has been reported for other kinds of cancers (8–10). It has previously been reported that PD-1/PD-L1 blockade rescued “exhausted” T cells, leading to the activation of T-cell effectors and transition to memory cells (7). The level of PD-1 occupancy on circulating T cells was shown to persist much longer than the serum half-life of the PD-1 antibodies (11, 12). This might mean that there is no need to perform continuous

---

**Table. Laboratory Data.**

|                          | Reference range | Before nivolumab | After 6 cycles of nivolumab |
|--------------------------|-----------------|------------------|-----------------------------|
| White blood cells /μL    | 4,000-9,000     | 3,500            | 3,400                       |
| Neutrophils %            | 45-55           | 47.8             | 47.7                        |
| Lymphocyte %             | 25-45           | 36.9             | 36.5                        |
| Hemoglobin g/dL          | 14-18           | 14.4             | 13.8                        |
| Platelets /μL            | 15-35×10⁴       | 11.3×10⁴         | 19.9×10⁴                    |
| Lactate dehydrogenase U/l| 106-211         | 155              | 249                         |
| Total bilirubin mg/dL    | 0.3-1.2         | 1.2              | 1.1                         |
| Sodium mEq/L             | 135-147         | 141              | 138                         |
| Potassium mEq/L          | 3.6-5.0         | 4.0              | 4.7                         |
| Chloride mEq/L           | 98-108          | 105              | 101                         |
| Calcium mg/dL            | 8.6-10.1        | 8.7              | 9.4                         |
| Urea nitrogen mg/dL      | 8-20            | 10.7             | 16.7                        |
| Creatinine mg/dL         | 0.61-1.04       | 0.95             | 1.00                        |
| C-reactive protein mg/dL | 0-0.2           | <0.03            | 0.46                        |
| Casual blood glucose mg/dL | 70-199          | –                | 192                         |
| Hemoglobin A1c %         | 4.6-6.2         | 5.5              | 5.4                         |
| CA19-9 U/mL              | <37.0           | 8.6              | –                           |
| CEA ng/mL                | ≤5.0            | 2.3              | –                           |
| TSH μU/mL                | 0.5-5.0         | 4.16             | 0.021                       |
| FT4 ng/dL                | 0.9-1.7         | 0.99             | 2.48                        |
| FT3 pg/mL                | 2.3-4.3         | 2.6              | 7.9                         |
| ACTH pg/mL               | 7.2-63.3        | 78.6             | 3.5                         |
| Cortisol μg/dL           | 7.07-19.6       | 14.6             | 0.2                         |
| GH ng/mL                 | 0.0-2.0         | –                | 1.2                         |
| LH mIU/mL                | 0.79-5.72       | –                | 6.1                         |
| FSH mIU/mL               | 2.00-8.30       | –                | 12.8                        |
| Prolactin ng/mL          | 4.29-13.69      | –                | 9.7                         |

ACTH: adrenocorticotropic hormone, CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen, FSH: follicle stimulating hormone, FT3: free triiodothyronine, FT4: free thyroxine, GH: growth hormone, LH: luteinizing hormone, TSH: thyroid stimulating hormone
treatment with ICIs. In fact, our patient showed that the metastatic lesions further decreased after the discontinuation of nivolumab.

Several predictive markers of an effective response to ICIs have been previously proposed for many cancers including AGC, such as better ECOG PS, no liver or lung metastases, a higher peripheral lymphocyte count, a lower neutrophil-lymphocyte ratio, a higher tumor PD-L1 expression, and a high degree of microsatellite instability (6, 13-17). However, there have been a limited number of case reviews about the predictive markers for a durable clinical benefit after the discontinuation of ICIs, namely only in melanoma and RCC cases (8, 10, 18). In the KEYNOTE-001 study on pembrolizumab in patients with melanoma, 61 of 67 patients (91.0%), who were followed up after pembrolizumab discontinuation after a complete response (CR), achieved a disease-free survival of 24 months (18). It was suggested that the patients with CR were more likely to achieve a durable response. A univariate analysis revealed that high CR rates were associated with a target tumor size between 1 and 5 cm and PD-L1-positive tumors (≥1% staining in tumor cells and mononuclear inflammatory cells) (18). A retrospective cohort study on melanoma patients showed that the risk of disease progression following treatment discontinuation was significantly associated with the overall response and it was lower in patients with CR (19). However, none of these conditions were seen in our patient (no CR, unknown tumor PD-L1 status, and target tumor size: 7.7 cm; data not shown). In addition, our patient did not exhibit any microsatellite instability (data not shown). Since the Epstein-Barr virus (EBV)-positive status might be a marker of an effective response to ICIs in AGC (20, 21), we performed EBV-encoded small RNA in situ hybridization on the primary tumor, which showed positivity in the nuclei of the tumor cells (Fig. 3). This result was consistent with that reported in previous reports (20, 21). However, there are no reports on the predictive markers for a durable clinical benefit after the discontinuation of ICIs in AGC, and further study in many similar cases will be needed to clarify this, regardless of the distinctive features seen in our patient.

Recent studies have shown that the development of irAE was associated with a clinical benefit in several cancers, including AGC (22-28). In NSCLC patients, in whom irAEs developed within 2 weeks from the start of nivolumab treatment (25), in whom more than two irAEs were reported (26), or in whom either endocrine irAEs or skin irAEs (28), a more pronounced benefit was observed. In melanoma cases, the occurrence of vitiligo as an irAE was associated with a clinical benefit (23, 29, 30), while endocrine irAE was not (23). In our patient, although the time to irAE occurrence was 15 weeks, which was longer than 2 weeks, two irAEs were detected, both of which were endocrine irAEs. The association between the types of irAEs and the clinical outcomes in different cancer types is still unclear.

ICIs induce multiple-organ irAEs via immune system overactivation (31). Two irAEs were observed in our patient. The incidence of endocrine irAEs varies depending on the agent, and nivolumab induces thyroid disorders in approximately 10% of such patients and hypophysitis in less than 1% of such patients (32, 33). A patient often shows the development of multiple irAEs, but the common patterns of irAEs have been rarely reported. Although the pathogenic mechanism of ICI-triggered hypophysitis is unknown, the characteristic symptoms and imaging findings resemble those of autoimmune hypophysitis (34), which was also seen in our patient. The current guidelines suggest corticosteroid therapy and the replacement of deficient hormones to man-

![Figure 2. The patient’s clinical course during nivolumab treatment. ACTH: adrenocorticotropin hormone, CORT: cortisol, FT4: free thyroxine, LT4: levothyroxine, PSL: prednisolone, TSH: thyroid stimulating hormone](image-url)
Figure 3. Hematoxylin and Eosin staining (A magnification 40×, C magnification 200×) and Epstein-Barr virus-encoded small RNA in situ hybridization (B magnification 40×, D magnification 200×) in the resected primary tumor.

...age endocrine irAEs (35), and long-term hormonal replacement is indicated for ACTH deficiency secondary to hypophysitis (36), which was also effective in our patient.

Recent studies have reported that recurrence of the same or different irAEs was observed in 18-52% of patients who received ICI re-administration (37-39), and these were milder than the initial events (38-40). A large-scale observational study using data from the World Health Organization database reported that colitis, hepatitis, and pneumonitis are associated with a higher recurrence rate, whereas adrenal events are associated with a lower recurrence rate compared with other irAEs (40). The efficacy of ICI re-administration is not yet established. A large retrospective analysis of NSCLC patients who were discontinued nivolumab therapy for any reason showed that OS in patients who received ICI re-administration was significantly better than that in patients who received chemotherapy only after nivolumab, in a sub-group analysis among the patients who initially received nivolumab therapy for more than 3 months (41). On the other hand, a retrospective cohort study on ICI re-administration in patients with solid tumors after the occurrence of an initial grade 2 or higher irAE showed that PFS in the re-administered patients was not better than that in the non-re-administered patients (38). If recurrence is observed in our case, then we will consider the re-administration of ICI while carefully monitoring irAEs.

In conclusion, we treated a patient with AGC who maintained a durable response for approximately 2 years after discontinuation of nivolumab. To the best of our knowledge, this is the first report to describe a durable clinical benefit after the discontinuation of nivolumab in gastric cancer. Further studies are necessary to elucidate the mechanism and the predictive markers of a durable clinical benefit after ICI discontinuation. The risks and benefits of ICI re-administration should be considered on the basis of the type of initial irAE.

The authors state that they have no Conflict of Interest (COI).

References

1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320-330, 2015.
2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.
3. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803-1813, 2015.
4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375: 1856-1867, 2016.
5. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the multicohort single-arm phase II checkMate 205 trial. J Clin Oncol 36: 1428-1439, 2018.
6. Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.

7. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22: 223-230, 2010.

8. Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M. Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of anti-PD-1 therapies due to immune-related adverse events. J Oncol 2019: 1856594, 2019.

9. Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115: 71-74, 2018.

10. Martini DJ, Hamieh L, McKay RR, et al. Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/ PD-L1 therapy for immune-related adverse events. Cancer Immunol Res 6: 402-408, 2018.

11. Brahmner JR, Drake CG, Wolfrun I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immuno-logic correlates. J Clin Oncol 28: 3167-3175, 2010.

12. Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3: e59125, 2018.

13. Tamiya M, Tamiya A, Inoue T, et al. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One 13: e0192227, 2018.

14. Okada N, Kawazoe H, Takechi K, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther 41: 59-67, 2019.

15. Fukui T, Okuma Y, Nakahara Y, et al. Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer 20: 208-214 e202, 2019.

16. Ogata T, Satake H, Ogata M, et al. Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget 9: 34520-34527, 2018.

17. Suzuki K, Terakawa T, Furukawa J, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol 25: 135-144, 2020.

18. Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36: 1668-1674, 2018.

19. Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 30: 1154-1161, 2019.

20. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24: 1449-1458, 2018.

21. Kubota Y, Kawaoze A, Sasaki A, et al. The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin Cancer Res 26: 3784-3790, 2020.

22. Masuda K, Shoji H, Nagashima K, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19: 974, 2019.

23. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22: 886-894, 2016.

24. Haratan K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4: 374-378, 2018.

25. Teraoka S, Fujimoto D, Morimoto T, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12: 1798-1805, 2017.

26. Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145: 479-485, 2019.

27. Shimozaki K, Sukawa Y, Beppu N, et al. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors. Cancer Manag Res Volume 12: 4585-4593, 2020.

28. Cortellini A, Chiari R, Ricciuti B, et al. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer 20: 237-247 e231, 2019.

29. Indini A, Di Guardo L, Cimmino J, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 145: 511-521, 2019.

30. Nakamura Y, Tanaka R, Asami Y, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivoluma: a multi-institutional retrospective study. J Dermatol 44: 117-122, 2017.

31. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26: 2375-2391, 2015.

32. Gonzalez-Rodriguez E, Rodriguez-Abrué D; Spanish Group for Cancer I-B. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804-816, 2016.

33. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated mela-noma. N Engl J Med 373: 23-34, 2015.

34. Caturegli P, Di Dalmaz G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186: 3225-3235, 2016.

35. Brahmner JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714-1768, 2018.

36. Del Rivero J, Cordes LM, Klubow-Gwiedzdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist 25: 290-300, 2020.

37. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29: 250-255, 2018.

38. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of read-ministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5: 1310-1317, 2019.

39. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6: 1093-1099, 2018.

40. Dolladille C, Elderly S, Sassiier M, et al. Immune checkpoint inhibi-tor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncology 6: 865-871, 2020.

41. Gaj Levra M, Cotté FE, Corre R, et al. Immunotherapy rechall-enge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis.
